scholarly journals Assessing the relationship between institutional cancer and diabetes mortality rates using National Death Index data

2020 ◽  
Vol 6 (10) ◽  
pp. FSO633
Author(s):  
Nina J Karlin ◽  
Matthew R Buras ◽  
Heidi E Kosiorek ◽  
Kyle E Coppola ◽  
Patricia M Verona ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Cancer Patients ◽  
Matched Pairs ◽  
Newly Diagnosed ◽  
National Death Index ◽  
Vital Status ◽  
Diabetes Mortality ◽  
Cancer Registry Data ◽  
Pancreatic Cancers ◽  
The Relationship

Aim: To evaluate overall survival (OS), glycemic control in cancer patients with and without diabetes mellitus (DM). Patients & methods: Patients (2010–2015) with newly diagnosed prostate, breast, lung, colorectal and pancreatic cancers were identified in institutional cancer registry. Data linked to National Death Index for vital status. 5-year OS estimated; glucose and hemoglobin A1c assessed during year postdiagnosis. Results: We identified 1404 patients (non-DM, n = 936; DM, n = 468). DM cohort had 168 deaths (36%); non-DM, 267 (29%). 5-year OS estimated at 58% (95% CI: 53–64%) for DM and 67% (95% CI: 64–71%) for controls; for matched pairs, hazard ratio: 1.35 (95% CI: 1.02–1.79). Cancer did not harm glycemic control. Conclusion: OS among cancer patients with DM was lower than without DM.

scholarly journals The Relationship Between Optimism and Quality of Life in Newly Diagnosed Cancer Patients

2010 ◽  
Vol 33 (3) ◽  
pp. 235-243 ◽  
Author(s):  
Susan R. Mazanec ◽  
Barbara J. Daly ◽  
Sara L. Douglas ◽  
Amy R. Lipson
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Newly Diagnosed ◽  
The Relationship

scholarly journals The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients

2009 ◽  
Vol 9 ◽  
pp. 1040-1045 ◽  
Author(s):  
Chad W. M. Ritenour ◽  
John T. Abbott ◽  
Michael Goodman ◽  
Naomi Alazraki ◽  
Fray F. Marshall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Bone Scan ◽  
Stage Migration ◽  
Gleason Grade ◽  
Newly Diagnosed ◽  
High Gleason Score ◽  
Bone Scans ◽  
The Relationship

Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%,p< 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p< 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p= 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.

Relationship between n-3 index, serum metabolites and breast cancer risk

2021 ◽  
Author(s):  
Jiaomei Li ◽  
Zhaohong Zheng ◽  
Min Liu ◽  
Yiping Ren ◽  
Yue Ruan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Serum Metabolites ◽  
The Relationship

The present study aimed to investigate the relationship between n-3 index, serum metabolites and breast cancer risk. A total of 104 newly diagnosed breast cancer patients and 70 healthy controls...

INVESTIGATION OF THE RELATIONSHIP BETWEEN THE RESPONSES TO CANCER AND RELIGIOUS COPING STYLES OF NEWLY DIAGNOSED BREAST CANCER PATIENTS

2021 ◽  
Vol 6 (11) ◽  
pp. 50-60
Author(s):  
Büşra ALTINTAŞ ◽  
Sibel DOĞAN
Keyword(s):  
Breast Cancer ◽  
Normal Distribution ◽  
Religious Coping ◽  
Cancer Patients ◽  
Subscale Score ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Scale Of Response ◽  
The Relationship ◽  
Positive Religious Coping

This research is a descriptive study conducted to assess the relationship between the responses to cancer by patients newly diagnosed with breast cancer and their religious coping.The study included 150 newly diagnosed breast cancer patients who received chemotherapy from November 2016/ April 2017 in the outpatient chemotherapy unit of a private university hospital. As a data collection tool, the questionnaire containing the descriptive and demographic characteristics of the patients, the scale of response style to cancer, and the religious coping style scale were used in the study. The data of the research were analyzed in terms of normal distribution by using the Shapiro-Wilks normality test. Since the data did not show normal distribution, the Mann-Whitney U test was used in two independent group comparisons, and the Kruskal-Wallis test was used in comparisons between more than two independent groups.Spearman correlation analysis was used to assess the relationship between scales. The predictive level of the Religious Coping Subscales to the Cancer Response subscale scores was evaluated by linear regression analysis. In the study, spiritual struggling subscale score within the scale of response to cancer was 51.81+4.95, the helplessness-despair subscale score was 9.85+2.39, anxious anticipate subscale score was 23.54+2.35, the fatalist subscale score was 19.98+1.59, and deny subscale score was 1.73+0.67.In other words, it was determined that the spiritual struggling soul was highly used by patients in response to cancer. In the study, the positive religious coping scale scores were 23.16+3.27, and negative religious coping scores were 7.72+1.77, which mean that most of the patients had positive religious coping scores. A positive correlation was found between the positive religious coping score and the spiritual struggling score (p<0.05; r=0.440). As the positive religious coping increases, the patients' struggle with disease is increasing. It has been observed that there is a relationship between cancer responses and religious coping of newly diagnosed breast cancer patients.

scholarly journals The Relationship Between Sarcopenia Detected In Newly Diagnosed Colorectal Cancer Patients And FGF21, Irisin And CRP Levels.

2021 ◽  
Author(s):  
Utku Oflazoglu ◽  
Sevinc Caglar ◽  
Huriye Erbak Yılmaz ◽  
Hülya Tas Önal ◽  
Umut Varol ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Negative Relationship ◽  
Newly Diagnosed ◽  
Skeletal Muscle Mass Index ◽  
Colorectal Cancer Patients ◽  
The Relationship

Abstract Aim: Sarcopenia is a progressive and generalized syndrome that can be linked to many causes such as cancers, and is caused by a quantitative and qualitative disorder (loss of muscle strength and / or physical performance) of skeletal muscle mass. Although sarcopenia has some hypothetical explanation in clinical practice, the mechanisms underlying this condition have not been clearly differentiated in patients with cancer. We aimed to investigate the relationship between irisin and FGF21 in detecting sarcopenia in colorectal cancer patients.Material and Method: Current prospectively study included non-metastatic newly diagnosed colorectal cancer patients. Patients were divided into two groups of 25 people, those with and without sarcopenia. Body composition measurements by examined by BIA. To measure the level of iris and FGF21 from patients, blood samples were taken into the biochemistry tube and their levels were measured. Results: The median age of the patients included in the study was 60 years (range: 21-81), 68 % were men. It was found that there was a significant relationship between sarcopenia and gender and BMI measurement. When Spearman correlation analysis was performed between skeletal muscle mass index and FGF21, irisin and CRP, there was a positive correlation between skeletal muscle mass index and irisin and FGF21, while there was a negative correlation between skeletal muscle mass index and CRP. [respectively: (r: 0.282, p: 0.048), (r: 0.564, p: <0.001) and (r: -0.360, p: 0.010). Similar results were found between hand grip strength and FGF21, irisin and CRP. [respectively: (r: 0.342, p: 0.015), (r: 0.290, p: 0.041) and (r: -0.476, p <0.001)]. When sarcopenia was treated as the dependent variable in the logistic regression analysis, and FGF21, irisin, CRP, gender and BMI were treated as the independent variables, irisin and CRP levels were determined as independent predictors. Conclusion: This study was revealed that there is a negative relationship between sarcopenia and irisin and FGF-21 in operated non-metastatic colorectal cancer patients and there may be a relationship between sarcopenia and inflammation. It suggest that these biomarkers may play a role in the pathophysiology of sarcopenia. However, our results need to be validated in different types of cancer and with more patients.

scholarly journals Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients

2020 ◽  
Author(s):  
Yan Huang ◽  
Xia Han ◽  
Feng-fei Li ◽  
Yan-mei Liu ◽  
Zelong Liu ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Mean Amplitude ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Mean Glucose ◽  
The Relationship ◽  
Type 2 Diabetic ◽  
Glycemic Variations

Abstract Background Accumulated evidences indicate that elevated levels of circulating ErbB2 are closely associated with increased incidence of diabetes. However, the relationship between ErbB2 concentration and glycemic variations (GV) in type 2 diabetic (T2D) patients remains elucidated. The aim of this study was to assess whether there is an association between serum ErbB2 concentration and GV in newly diagnosed T2D patients. Methods This was a three-center, and observational study. Between April 2019 and July 2019, a total of 106 newly diagnosed T2D patients were recruited. All recruited subjects were admitted as inpatients and received anti-diabetes agents free during the study period. At baseline, fasting serum was collected for ErbB2 measurement and all recruited patients were subjected a prospective CGM for at least 3 days. The primary endpoint was the relationships between ErbB2 concentrations and GV in T2D patients. Results Data of a total of 95 subjects who met the inclusion criteria were analyzed at the endpoint. Subjects were divided into quartiles according to their serum ErbB2 concentrations. We observed that subjects with an elevated level of ErbB2 had a higher value of GV in terms of mean amplitude of glucose excursion (MAGE), standard deviation of mean glucose (SDMG), and the coefficient of variation (CV%) than those with lower levels (all P<0.05). Multiple linear regression analyzes after adjusting for confounder factors indicate that serum ErbB2 levels were significantly positively correlated with the MAGE (β=0.664, t=7.218, P<0.01), SD (β=0.469, t=5.125, P<0.01) and CV% (β=0.337, t=4.442, P<0.01), respectively. Conclusion Serum ErbB2 concentration was positively correlated to the glycemic variations in newly diagnosed T2D patients. Our data indicating that ErbB2 may be a potential treatment target for diabetic patients for improvement in glycemic control. Keywords Type 2 Diabetes, glycemic control, ErbB2

Influenza and mortality for non-small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13114-e13114
Author(s):  
Connor J Kinslow ◽  
Yuankun Wang ◽  
Yi Liu ◽  
Konstantin M. Zuev ◽  
Tony J. C. Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Mortality Rates ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Influenza Illness ◽  
The Relationship

e13114 Background: Lung cancer is the leading cause of cancer deaths in the United States and worldwide. While influenza illness is known to be particularly dangerous for frail and elderly patients, the relationship between influenza illness and outcomes in cancer patients remains largely unknown. Methods: Monthly mortality rates for all patients at risk, as well as newly diagnosed patients, with non-small cell lung cancer (NSCLC) diagnosed between 2009 and 2015 were compared during high and low flu months using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Center for Disease Control and Prevention (CDC) website. Influenza severity was determined by the percentage of outpatient visits to healthcare providers for influenza-like illness (ILI). CDC ILI activity levels were matched with SEER data by month and state. State-months with an ILI activity level of 8 or higher were considered to be high flu months, as defined by the CDC. Results: 195,038 patients with NSCLC from 13 states were included in the analysis. 52 out of 1,081 state-months (5.1%) had high flu activity. Monthly mortality rates for low and high flu months were 4.9 and 5.7%, respectively (p = .001). The monthly mortality rate for newly diagnosed patients was also significantly higher during high flu months (9.4 vs. 10.2%, p = .01). When the analysis was limited to winter months only, monthly mortality rates for low and high flu months were 4.7 and 5.3%, respectively (p = .02). The relationship between flu severity and mortality was also observed at the individual state level. Conclusions: Increased influenza severity is associated with higher mortality rates for NSCLC patients. Future research should elucidate the relationship between vaccination and survival in lung cancer patients.

Rising thyroid cancer incidence in Kerala: Is it real or over diagnosis?

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17589-e17589
Author(s):  
Saadvik Raghuram ◽  
Bharadwaj Ponnada ◽  
Pavithran Keechilat
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Clinical Symptoms ◽  
P Value ◽  
Newly Diagnosed ◽  
Main Mode ◽  
Screening Programs ◽  
Cancer Registry Data ◽  
Initial Surgery ◽  
Mode Of Detection

e17589 Background: There has been an increase in the incidence of thyroid cancer in India and in high income countries. One of the reasons for this has been attributed to the large number of screening programs. Kerala state ranks second highest in the incidence of thyroid cancer in India. Screening provides the advantage of early detection of cancer and successful treatment but also tends to over diagnose. Methods: To study the trend of incidence of primary thyroid cancer among newly diagnosed cancer patients and its association with the mode of detection, we retrospectively reviewed hospital based cancer registry data of patients with thyroid cancer who were treated at AIMS (Amrita Institute of Medical Sciences), Kochi between 2004-2014. All patients who were newly diagnosed with primary thyroid cancer at our center or referred to us after initial surgery were included in this analysis. Patients with recurrent cancer/metastases were excluded. Results: We analyzed the records of 2,315 newly diagnosed thyroid cancer patients. Median age was 44.1yrs (range 13-90yrs). There were 619 males and 1696 females. Papillary type was the most common 85.8% followed by follicular type 7.4%. 1235 cases were operated at AIMS. 74 cases (3.2%) were diagnosed incidentally by Ultrasonography/PET scan/CT scan. All others (97% n = 2,245) presented with neck swelling. It was seen that the proportion of new cases of thyroid cancer among all new cancer cases was increasing serially from 4.6 % (n = 106, 95% 2004) to 7.4% (n = 195) to13.7% (n = 317, 2014). There was a significant increase in the number of cases of T1a and T1b at the time of diagnosis during the study period (n = 1235, p value < 0.001 and p value for trend < 0.001 respectively) which indicates that there was early diagnosis. 97% of the cases presented with thyroid related symptoms indicating that clinical presentation has still been the main mode of detection in our series. Conclusions: Our data shows that there may be a true increase in the number of cases of thyroid cancer as majority presented with clinical symptoms, except few detected incidentally. As it is a single institution based data we need further studies to see if over use of USG based imaging for any thyroid swelling is responsible for an apparent increase in the number of thyroid cancer cases.

Mortality and glycemic control among patients with gastric and esophageal cancer and diabetes mellitus.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 73-73
Author(s):  
Nina J. Karlin ◽  
Matthew Buras ◽  
Heidi E. Kosiorek ◽  
Patricia M. Verona ◽  
Curtiss B. Cook
Keyword(s):  
Diabetes Mellitus ◽  
Esophageal Cancer ◽  
Glycemic Control ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Cox Regression ◽  
Hazard Ratio ◽  
Matched Pairs ◽  
Cox Regression Analysis ◽  
The Impact

73 Background: This study evaluated the impact of diabetes mellitus (DM) on survival in gastric and esophageal cancer patients, and examined the impact of these cancers on glycemic control in DM. Methods: Patients with newly diagnosed gastric and esophageal cancers with DM (n = 92) were identified from the Institutional Cancer Registry and matched to 92 gastric and esophageal cancer patients without DM according to age, gender and year of cancer diagnosis (2006 to 2016). The electronic medical record provided information on DM and cancer therapies and laboratory results. Overall survival (OS) was estimated with the Kaplan-Meier method and compared by Cox regression analysis using stratification for matched pairs. Mixed models were used to compare hemoglobin A1c (HbA1c) and glucose during the year following cancer diagnosis. Results: Mean age of the entire cohort was 68 years, 91% were white, 78% were men, and 53% had stage III/IV disease. Adenocarcinoma (79%) was the most common histologic type. BMI was significantly different between DM and non-DM patients (p = 0.006). Alcohol use at time of cancer diagnosis was more prevalent in non-DM patients vs. DM (p = 0.018). Among those with DM, mean HbA1c during the year following cancer diagnosis was 6.8%. Mean glucose was significantly different between DM and non-DM patients (149 mg/dL vs. 116 mg/dL, p < 0.001). For glucose, there was a significant interaction effect (p = 0.005) as DM patients demonstrated a decrease in glucose values over time compared to non-DM patients. Median follow-up time was 35 months. Three year OS was estimated at 46% (95% CI: 36-58%) for DM patients versus 52.0% (95% CI: 41-64%) in non-DM (p = 0.25). Hazard ratio (stratification for matched pairs) was 1.95 (95% CI: 1.14 – 3.43; p = 0.02). Three year PFS was estimated at 40% (95% CI: 31-53%) for DM patients versus 50% (95% CI: 40-63%) for non-DM patients (p = 0.12). Hazard ratio (stratification for matched pairs) was 1.74 (95% CI: 1.04-2.90; p = 0.03). Conclusions: Gastric and esophageal cancer and its treatment did not affect glycemic control. Risks of death and progression are greater in DM patients as compared to non-DM.

Sign in / Sign up

Export Citation Format

Share Document